Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286

Nivolumab plus Ipilimumab in Advanced Melanoma

Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230

Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer

Percik, R., Criseno, S., Adam, S., Young, K., & Morganstein, D. L. (2023) · Endocrine Connections · doi:10.1530/ec-22-0513 · Cited by 28

Nebenwirkungsmanagement bei Immun‐Checkpoint‐Blockade durch CTLA‐4‐ und PD‐1‐Antikörper beim metastasierten Melanom – ein Update

Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Thoms, K., Ugurel, S., Zimmer, L., Gutzmer, R., & (ADO), F. D. K. „. N. D. A. D. O. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14128_g · Cited by 27

Lymphocytic Hypophysitis Successfully Treated with Stereotactic Radiosurgery: Case Report and Review of the Literature

Bogosavljević, V., Peker, S., Doknić, M., Miljić, D., Stojanović, M., Skender-Gazibara, M., Manojlović-Gačić, E., POPOVIC, V. M., Petakov, M. S., & Pekić, S. (2017) · Journal of Neurological Surgery Part A Central European Neurosurgery · doi:10.1055/s-0037-1604079 · Cited by 27

Multimodality imaging of endocrine immune related adverse events: a primer for radiologists

Alessandrino, F., Shah, H., & Ramaiya, N. H. (2018) · Clinical Imaging · doi:10.1016/j.clinimag.2017.12.014 · Cited by 27

Acute Oncology Care: A narrative review of the acute management of neutropenic sepsis and immune-related toxicities of checkpoint inhibitors

Knight, T., Ahn, S., Rice, T. W., & Cooksley, T. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.09.025 · Cited by 28

Endocrine toxicity of cancer immunotherapy: clinical challenges

Anderson, B., & Morganstein, D. L. (2021) · Endocrine Connections · doi:10.1530/ec-20-0489 · Cited by 26

Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review

Heng, J. S., Kim, J. M., Jones, D. K., STOESSEL, K. M., Weiss, S. A., Sznol, M., Kluger, H. M., Walter, S. D., Silverstein, N. A., & Pointdujour‐Lim, R. (2022) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2021-000889 · Cited by 26

Immune checkpoint inhibitor therapy for pediatric cancers: A mini review of endocrine adverse events

Ihara, K. (2019) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.28.59 · Cited by 26

Check point inhibitors and autoimmunity: Why endocrinopathies and who is prone to?

Percik, R., & Shoenfeld, Y. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101411 · Cited by 26

Fulminant type 1 diabetes associated with Isolated ACTH deficiency induced by anti-programmed cell death 1 antibody—insight into the pathogenesis of autoimmune endocrinopathy—

Okahata, S., Sakamoto, K., Mitsumatsu, T., Kondo, Y., Noso, S., Ikegami, H., & Shiba, T. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0328 · Cited by 25

Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents

Шубникова, Е. В., Букатина, Т. М., Velts, N. Y., Kaperko, D. A., & Кутехова, Г. В. (2020) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2020-8-1-9-22 · Cited by 26

Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor

Suteau, V., Collin, A., Meneï, P., Rodien, P., Rousselet, M., & Briet, C. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02611-x · Cited by 24

Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy

Ho, A. K., Ho, A. M. ‐., Cooksley, T., Nguyen, G., Erb, J., & Mizubuti, G. B. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005029 · Cited by 24

Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency

Manaka, K., Sato, J., Takeuchi, M., Watanabe, K., Kage, H., Kawai, T., Sato, Y., Miyagawa, T., Yamada, D., Kume, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91032-6 · Cited by 23

Melanoma and immunotherapy bridge 2015

Nanda, V. G. Y., Peng, W., Hwu, P., Davies, M. A., Ciliberto, G., Fattore, L., Malpicci, D., Aurisicchio, L., Ascierto, P. A., Croce, C. M., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0791-2 · Cited by 22

Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non–Small Cell Lung Cancer

Shroff, G. S., Strange, C. D., Ahuja, J., Altan, M., Sheshadri, A., Ünlü, E., Truong, M. T., & Vlahos, I. (2022) · Radiographics · doi:10.1148/rg.220108 · Cited by 22

Adverse Effects of Immune-Checkpoint Inhibitors: A Comprehensive Imaging-Oriented Review

Mallio, C. A., Bernetti, C., Cea, L., Buoso, A., Stiffi, M., Vertulli, D., Greco, F., & Zobel, B. B. (2023) · Current Oncology · doi:10.3390/curroncol30050355 · Cited by 23

New Molecular, Biological, and Immunological Agents Inducing Hypophysitis

Angelousi, A. G., Chatzellis, E., & Kaltsas, G. (2017) · Neuroendocrinology · doi:10.1159/000480086 · Cited by 22

Adverse effects and radiological manifestations of new immunotherapy agents

Tang, Y. Z., Szabados, B. E., Leung, C., & Sahdev, A. (2018) · British Journal of Radiology · doi:10.1259/bjr.20180164 · Cited by 22

Thyroiditis and immune check point inhibitors: the post‐marketing experience using the French National Pharmacovigilance database

Garon-Czmil, J., Petitpain, N., Rouby, F., Sassier, M., Babai, S., Yelehe‐Okouma, M., Weryha, G., Klein, M., & Gillet, P. (2018) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12423 · Cited by 23

Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?

Music, M., Prassas, I., & Diamandis, E. P. (2018) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2018.1499706 · Cited by 21

Late-onset hypophysitis after discontinuation of nivolumab treatment for advanced skin melanoma: a case report

Antoniou, S., Bazazo, G., Röckl, L., Papadakis, M., & Berg, C. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00854-y · Cited by 21

Endocrine dysfunction following immune checkpoint inhibitor therapy

Konda, B., Nabhan, F. A., & Shah, M. H. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000357 · Cited by 20

Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report

Tanaka, S., Kushimoto, M., Nishizawa, T., Takubo, M., Mitsuke, K., Ikeda, J., Fujishiro, M., Ogawa, K., Tsujino, I., Suzuki, Y., et al. (2020) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-019-0092-9 · Cited by 20

Less known aspects of central hypothyroidism: Part 1- Acquired etiologies

Benvenga, S., Klose, M., Vita, R., & Feldt-Rasmussen, U. (2018) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2018.09.003 · Cited by 19

Update in Immunotherapy for Advanced Non-Small Cell Lung Cancer: Optimizing Treatment Sequencing and Identifying the Best Choices

Roque, K., Ruiz, R., Mas, L. A., Pozza, D. H., Vancini, M., Silva, J. A., & de Mello, R. A. (2023) · Cancers · doi:10.3390/cancers15184547 · Cited by 19

Primary and Ipilimumab-induced Hypophysitis: A Single-center Case Series

Atkins, P., & Ur, E. (2020) · Endocrine Research · doi:10.1080/07435800.2020.1817064 · Cited by 19

Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management

Kotwal, A. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000652 · Cited by 18

Endocrinopathies from checkpoint inhibitors: Incidence, outcomes, and management

Kennedy, R., Awada, H., Vura, N. V. R. K., Ciltea, D., & Morocco, M. (2023) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.90a.22032 · Cited by 20

Endocrinopathies Associated With Immune Checkpoint Inhibitor Use

Kotwal, A., Kennedy, R., Kikani, N. J., Thosani, S., Goldner, W. S., & Shariff, A. I. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.03.023 · Cited by 20

Nivolumab-induced Adrenal Insufficiency in Patients With Renal Cell Carcinoma

Suzuki, K., Terakawa, T., Furukawa, J., Harada, K., Hinata, N., Nakano, Y., & Fujisawa, M. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000299 · Cited by 18

Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review

Dudzińska, M., Szczyrek, M., Wojas‐Krawczyk, K., Świrska, J., Chmielewska, I., & Zwolak, A. (2020) · Cancers · doi:10.3390/cancers12082314 · Cited by 19

Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report

Deng, C., Yang, M., Jiang, H., Wang, R., Yang, Z., Sun, H., & Cui, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.664809 · Cited by 18

Pituitary Dysfunction: A Case Series of Immune Checkpoint Inhibitor–Related Hypophysitis in an Emergency Department

Miller, A. H., Brock, P. A., & Yeung, S. J. (2016) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2016.03.048 · Cited by 18

Immunotherapy-Related Hypophysitis: A Narrative Review

Stasi, V. D., Sala, D. L., Cozzi, R. C., Scavuzzo, F., Geronimo, V. D., Poggi, M., Vitale, M., & Tortora, A. (2025) · Cancers · doi:10.3390/cancers17030436 · Cited by 19

Acute Oncologic Complications: Clinical–Therapeutic Management in Critical Care and Emergency Departments

Gri, N., Longhitano, Y., Zanza, C., Monticone, V., Fuschi, D., Piccioni, A., Bellou, A., Esposito, C., Ceresa, I. F., & Savioli, G. (2023) · Current Oncology · doi:10.3390/curroncol30080531 · Cited by 17

Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma

Mishima, Y., Fukaishi, T., Inase, N., & Isogai, S. (2018) · Internal Medicine · doi:10.2169/internalmedicine.1268-18 · Cited by 17

Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer

Chang, J., Tran, J. S., Kamel, D., & Basu, A. (2019) · BMJ Case Reports · doi:10.1136/bcr-2018-228135 · Cited by 17

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related adverse reactions in the nervous system

Shi, J., Niu, J., Shen, D., Liu, M., Tan, Y. K., Li, Y., huang, Y., Cui, L., Guan, Y., & Zhang, L. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13266 · Cited by 17

Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH

Siddiqui, M. S., Lai, Z. M., Spain, L. A., Greener, V., Turajlic, S., Larkin, J., & Morganstein, D. L. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01297-3 · Cited by 17

New-onset graves’ disease after the initiation of nivolumab therapy for gastric cancer: A case report

Yamada, H., Okajima, F., Onda, T., Fujimori, S., Emoto, N., & Sugihara, H. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00613-5 · Cited by 17

A pituitary metastasis, an adenoma and potential hypophysitis: A case report of tumour to tumour metastasis in the pituitary

Castle‐Kirszbaum, M., Phung, T. B., Luen, S. J., Rimmer, J., Chandra, R. V., & Goldschlager, T. (2020) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2020.09.033 · Cited by 17

Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies

George, A. S., Fernandez, C. J., Eapen, D., & Pappachan, J. M. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.17.1.21 · Cited by 18

Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy

Chye, A., Allen, I., Barnet, M. B., & Burnett, D. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894015 · Cited by 17

The side effects of immune checkpoint inhibitor therapy on the endocrine system

Goyal, I., Pandey, M. R., Sharma, R. K., Chaudhuri, A., & Dandona, P. (2021) · International Journal of Microbiology Research · doi:10.4103/ijmr.ijmr_313_19 · Cited by 18

Review on Recent Topics in Hypophysitis

Sugihara, H. (2017) · Journal of Nippon Medical School · doi:10.1272/jnms.84.201 · Cited by 17

PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas

Cossu, G., Rosa, S. L., Brouland, J., Pitteloud, N., Harel, E., Santoni, F. A., Brunner, M., Daniel, R. T., & Messerer, M. (2023) · Cancers · doi:10.3390/cancers15184471 · Cited by 16

Immune-related endocrine disorders in novel immune checkpoint inhibition therapy

Min, L. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.10.002 · Cited by 16

Hypophysitis — new insights into diagnosis and treatment

Kluczyński, Ł., Gilis‐Januszewska, A., Rogoziński, D., Pantofliński, J., & Hubalewska–Dydejczyk, A. (2019) · Endokrynologia Polska · doi:10.5603/ep.a2019.0015 · Cited by 16

Progress and Challenges of Immune Checkpoint Inhibitor-Induced Hypophysitis

Chen, P. L., Li, J., & Tan, H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103468 · Cited by 16

Neurotoxicity of antibodies in cancer therapy: A review

Horta, E. S., Bongiorno, C. M., Ezzeddine, M. A., & Neil, E. C. (2019) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2019.105566 · Cited by 15

Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy

Brilli, L., Calabrò, L., Campanile, M., Pilli, T., Agostinis, C., Cerase, A., Maio, M., & Castagna, M. G. (2020) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000221 · Cited by 15

Hypophysitis

Donegan, D. M., & Honegger, J. B. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.06.009 · Cited by 15

Clinical Interrogation for Unveiling an Isolated Hypophysitis Mimicking Pituitary Adenoma

Lee, S., Choi, J. H., Kim, C. J., & Kim, J. H. (2016) · World Neurosurgery · doi:10.1016/j.wneu.2016.07.071 · Cited by 15

The Diagnosis and Management of Endocrine Side Effects of Immune Checkpoint Inhibitors

Mai, K., Faßnacht, M., Führer‐Sakel, D., Honegger, J. B., Weber, M. M., & Kroiß, M. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0143 · Cited by 15

Common endocrine system adverse events associated with immune checkpoint inhibitors

Li, Y., Zhao, J., Wang, Y., Xu, Y., Li, R., Zhao, Y., Dong, X., Yao, X., & Li, Y. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.11.005 · Cited by 14

Checkpoint inhibitor-associated autoimmunity

Ladak, K., & Bass, A. R. (2018) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.03.009 · Cited by 14

Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features

Esteves-Ferreira, S., & Rosinha, P. M. O. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04659-5 · Cited by 14

Immune checkpoint inhibitor therapy-induced hypophysitis ∼ a case series of Taiwanese patients

Lin, C., Chen, K., Chen, K., Shih, S., & Lu, J. (2018) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.07.014 · Cited by 14

Diabetes insipidus: A rare endocrine complication of immune check point inhibitors: A case report and literature review

Angelousi, A. G., Papalexis, P., Karampela, A., Marra, M., Misthos, D., Ziogas, D. I., & Gogas, H. J. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11709 · Cited by 13

Clinical practice and mechanism of endocrinological adverse events associated with immune checkpoint inhibitors

Iwama, S., & Arima, H. (2017) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.40.90 · Cited by 13

Checkpoint Inhibitor-Associated Hypophysitis

Chang, L., & Yialamas, M. A. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-017-4135-6 · Cited by 13

Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer

Ida, H., Goto, Y., Sato, J., Kanda, S., Shinno, Y., Morita, R., Murakami, S., Matsumoto, Y., Yoshida, T., Horinouchi, H., et al. (2020) · Medical Oncology · doi:10.1007/s12032-020-01357-x · Cited by 13

The risk of endocrine immune-related adverse events induced by PD-1 inhibitors in cancer patients: a systematic review and meta-analysis

Zhao, P., Zhao, T., Yu, L., Ma, W., Liu, W., & Zhang, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1381250 · Cited by 14

Introduction to expert opinion on endocrine complications of new anticancer therapies

Castinetti, F., & Borson‐Chazot, F. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.07.001 · Cited by 12

Clinical Course and Management of Pembrolizumab-Associated Isolated Adrenocorticotrophic Hormone Deficiency: A New Case and Literature Review

Oğuz, S. H., Ünlütürk, U., Aksoy, S., & Erbas, T. A. (2021) · Immunotherapy · doi:10.2217/imt-2021-0061 · Cited by 12

Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events

Kobayashi, T., Iwama, S., & Arima, H. (2023) · Endocrine Journal · doi:10.1507/endocrj.ej23-0524 · Cited by 12

PD-L1 Expression in Normal Endocrine Tissues Is Not Increased Despite High Incidence of PD-1 Inhibitor-Associated Endocrinopathies

Pollack, R. M., Kagan, M., Dresner–Pollak, R., & Neuman, T. (2020) · Endocrine Practice · doi:10.1016/j.eprac.2020.11.004 · Cited by 12

Autoimmune diabetes insipidus

Scherbaum, W. A. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-820683-6.00015-4 · Cited by 12

Nivolumab-induced hypophysitis followed by acute-onset type 1 diabetes with renal cell carcinoma: a case report

Kikuchi, F., Saheki, T., Imachi, H., Kobayashi, T., Fukunaga, K., Ibata, T., Sato, S., Ban, N., Lyu, J., Japar, S., et al. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-020-02656-7 · Cited by 11

Endocrine Dysfunction From Immune Checkpoint Inhibitors: Pearls and Pitfalls in Evaluation and Management

Kotwal, A., Perlman, J. E., Goldner, W. S., Marr, A., & Mammen, J. S. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00023 · Cited by 11

Immunotherapy-induced autoimmune diabetes and concomitant hypophysitis

Sum, M., & Vallejo, F. (2018) · Pituitary · doi:10.1007/s11102-018-0880-8 · Cited by 11

Isolated adrenocorticotropic hormone deficiency potentially induced by nivolumab following pseudo‑progression in clear cell renal cell carcinoma: A case report

Furubayashi, N., Negishi, T., Uozumi, T., Takamatsu, D., Shiraishi, K., Hirose, D., & Nakamura, M. (2018) · Molecular and Clinical Oncology · doi:10.3892/mco.2018.1781 · Cited by 11

Clinical and radiological diagnosis of hypophysitis: a review of literature and own data

Vorontsov, A. V., Мажлумовна, Б. Д., Vladimirova, V. P., Dubovitskaya, Т. A., Gavrilova, A. O., Belaya, Z. E., & Mokrysheva, N. (2022) · Problems of Endocrinology · doi:10.14341/probl12777 · Cited by 11

Nebenwirkungsmanagement bei Immun‐Checkpoint‐Blockade durch CTLA‐4‐ und PD1‐Antikörper beim metastasierten Melanom

Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Mößner, R., Ugurel, S., Zimmer, L., Gutzmer, R., & (ADO), F. D. K. „. N. D. A. D. O. (2016) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13047_g · Cited by 11

Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review

Lin, S.-H., Zhang, A., Li, L.-Z., Zhao, L.-C., Wu, L., & Fang, C. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01151-y · Cited by 11

Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis

Galligan, A., Iravani, A., Lasocki, A., Wallace, R., Weppler, A. M., Sachithanandan, N., Chiang, C. Y., Colman, P. G., Wentworth, J. M., Spain, L. A., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1295865 · Cited by 10

Endocrine dysfunctions during treatment of immune-checkpoint inhibitors

Inaba, H., Ariyasu, H., Okuhira, H., Yamamoto, Y., Akamatsu, H., Katsuda, M., Jinnin, M., Hara, I., & Akamizu, T. (2018) · Trends in Immunotherapy · doi:10.24294/ti.v2.i2.606 · Cited by 10

Endocrine dysfunction induced by immune checkpoint inhibitors.

Deligiannis, N. G., Sosa, S., Danilowicz, K., & Rizzo, L. F. L. (2021) · PubMed · Cited by 10

Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy: 6.5 Year Follow-Up

Gutkin, P. M., Hiniker, S. M., Swetter, S. M., Reddy, S. A., & Knox, S. J. (2018) · Cureus · doi:10.7759/cureus.3723 · Cited by 10

Imaging spectrum of adverse events of immune checkpoint inhibitors

Shroff, G. S., Shroff, S., Ahuja, J., Truong, M. T., & Vlahos, I. (2020) · Clinical Radiology · doi:10.1016/j.crad.2020.11.117 · Cited by 9

Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review

Lyadova, M. A., & Lyadov, V. K. (2021) · Journal of Modern Oncology · doi:10.26442/18151434.2021.2.200502 · Cited by 10

Three cases of immune-related hypopituitarism after atezolizumab–bevacizumab treatment for hepatocellular carcinoma

Furuichi, N., Naganuma, A., Kaburagi, T., Suzuki, Y., Hoshino, T., Shibusawa, N., Horiguchi, S., Hatanaka, T., Kakizaki, S., & Uraoka, T. (2023) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-023-01775-0 · Cited by 9

Endocrine Toxicities of Antineoplastic Therapy

Puliani, G., & Appetecchia, M. (2021) · Cancers · doi:10.3390/cancers13020294 · Cited by 9

Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies

Bellastella, G., Carbone, C., Scappaticcio, L., Cirillo, P., Troiani, T., Morgillo, F., Vietri, M. T., Corte, C. M. D., Falco, V. D., Napolitano, S., et al. (2021) · Cancers · doi:10.3390/cancers13164036 · Cited by 9

Hypophysitis: A rare but noteworthy immune-related adverse event secondary to camrelizumab therapy

Han, X., Meng, M., Zhang, T., Wang, J., Huang, G., Ni, Y., Li, W., Dai, J., Yang, X., & Ye, X. (2022) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_831_21 · Cited by 9

Restored vision in a young dog following corticosteroid treatment of presumptive hypophysitis

Rzechorzek, N. M., Liuti, T., Stalin, C. E., & Marioni‐Henry, K. (2016) · BMC Veterinary Research · doi:10.1186/s12917-017-0983-x · Cited by 9

Incidence and Risk of Thyroid Dysfunction in Advanced or Metastatic Non-small Cell Lung Cancer Patients Treated with Pembrolizumab: A Meta-analysis

Abid, H., Khavandi, M., Siddiqui, N., Panjawatanan, P., & Patel, A. V. (2019) · Cureus · doi:10.7759/cureus.5997 · Cited by 9

Hypophysites induites par les immunothérapies anti-néoplasiques

du Payrat, J. A., Cugnet‐Anceau, C., Maillet, D., Levy, M., Raverot, G., Disse, E., & Borson‐Chazot, F. (2020) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.01.012 · Cited by 9

Adrenal Insufficiency From Immune Checkpoint Inhibitors Masquerading as Sepsis

Abdallah, D., Johnson, J. N., Goldner, W. S., Addasi, N., Desouza, C. V., & Kotwal, A. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00781 · Cited by 9

Hypopituitarism: genetic, developmental, and acquired etiologies with a focus on the emerging concept of autoimmune hypophysitis

Bando, H., Urai, S., Kanie, K., & Yamamoto, M. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej25-0035 · Cited by 8

Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know

Shah, M., Rajha, E., Dinardo, C. D., Muckey, E., Wierda, W. G., & Yeung, S. J. (2019) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2019.07.015 · Cited by 8

Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin?

Chiloiro, S., Giampietro, A., Bianchi, A., Menotti, S., Angelini, F., Tartaglione, T., Cappellini, G. A., Galitiis, F. D., Rossi, E., Schinzari, G., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030415 · Cited by 8

Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report

Iesaka, H., Kameda, H., Miya, A., Nomoto, H., Cho, K. Y., Nakamura, A., Abe, T., Shinohara, N., & Atsumi, T. (2023) · Medicine · doi:10.1097/md.0000000000036664 · Cited by 8

Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery

Tanaka, F., Kogue, R., Maeda, M., Umino, M., Nakai, Y., Takeshita, A., & Sakuma, H. (2017) · Radiology Case Reports · doi:10.1016/j.radcr.2017.11.007 · Cited by 8

Exploring a New Entity of Single-Agent Pembrolizumab-Associated Hypophysitis

Balti, E. V., Verhaeghe, S., Krüse, V., Roels, S., & Coremans, P. (2022) · Cureus · doi:10.7759/cureus.27763 · Cited by 8

Immunotherapy-Associated Hypophysitis under Anti-PD1: Two Case Reports

Ma, J., Shen, X., Yang, M., Xu, H., Zhou, H., & Wang, L. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666221208111823 · Cited by 8

Replacement with sex steroids in hypopituitary men and women: implications for gender differences in morbidities and mortality

Donald, D. M., McDonnell, T., O’Reilly, M., & Sherlock, M. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09897-7 · Cited by 7

Neuroimaging of central diabetes insipidus

Farrell, T. P., Adams, N., & Looby, S. T. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-820683-6.00016-6 · Cited by 7

Pituitary and adrenal disorders induced by immune checkpoint inhibitors

Albarel, F., Brue, T. C., & Castinetti, F. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.03.014 · Cited by 7

Managing Ipilimumab-Induced Hypophysitis: Challenges and Current Therapeutic Strategies

Tsoli, M., Kaltsas, G., Angelousi, A. G., Alexandraki, K., Randeva, H. S., & Kassi, E. N. (2020) · Cancer Management and Research · doi:10.2147/cmar.s224791 · Cited by 41

Ipilumumab induced hypophysitis

Craus, S., Imbroll, M. G., & Gruppetta, M. (2019) · Endocrine Abstracts · doi:10.1530/endoabs.63.p279

Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab

Brilli, L., Danielli, R., Ciuoli, C., Calabrò, L., Giacomo, A. M. D., Cerase, A., Paffetti, P., Sestini, F., Porcelli, B., Maio, M., et al. (2017) · Endocrine · doi:10.1007/s12020-017-1289-2 · Cited by 45

Immune-related hypophysitis in three patients with metastatic melanoma undergoing Ipilimumab treatment

Tsioga, M., Voigtlaender, R., Suttorp, W., Zimmer, L., Schlamann, M., Sure, U., Lahner, H., Moeller, L., & Fuehrer, D. C. (2013) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0033-1336692

Secondary hypophysitis due to immune checkpoint inhibitors – case report and literature review

UMF Carol Davila Bucharest, R., Ilie, I., Septar, A., Hortopan, D., Caragheorgheopol, A., Iordachescu, C. N., Alexiu, F., Elian, V., Banica, A., Oprea, L., et al. (2019) · ROMANIAN BIOTECHNOLOGICAL LETTERS · doi:10.25083/rbl/24.3/412.417